Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Nov;479(5):1041-1046.
doi: 10.1007/s00428-021-03073-x. Epub 2021 Mar 10.

A systemic apolipoprotein A-IV-associated amyloidosis confirmed by proteome analysis

Taro Murakami  1 , Akira Takasawa  2 , Asako Moriki  1   3 , Yusuke Igaki  4 , Hiroshi Ikeda  5 , Kazuyuki Murase  5 , Kohichi Takada  5 , Kazufumi Magara  1 , Tomoyuki Aoyama  1 , Yusuke Ono  1 , Daisuke Kyuno  1 , Kumi Takasawa  1 , Masaki Murata  1   6 , Makoto Osanai  1
Affiliations
Case Reports

A systemic apolipoprotein A-IV-associated amyloidosis confirmed by proteome analysis

Taro Murakami et al. Virchows Arch. 2021 Nov.

Abstract

Amyloidosis is induced by extracellular deposition of certain proteins. Thirty-six proteins have so far been identified as amyloidogenic proteins in humans. Although it is very important to determine the specific amyloid protein type for the choice of therapy for amyloidosis patient, it might be difficult to identify specific proteins from amyloid-deposited tissue. Apolipoprotein A-IV is known as an amyloid-associated protein, but there have been few reports of apolipoprotein A-IV amyloidosis. Here we report a case of systemic apolipoprotein A-IV-associated amyloidosis that was confirmed by proteome analysis using formalin-fixed paraffin-embedded tissue and an immunohistochemical technique.

Keywords: Amyloidosis; Apolipoprotein A-IV; Formalin-fixed paraffin-embedded tissue; Proteome analysis.

PubMed Disclaimer

References

    1. Dasari S, Amin MS, Kurtin PJ, Vrana JA, Theis JD, Grogg KL, Alexander MP, Nasr SH, Fervenza FC, Leung N, Sethi S (2016) Clinical biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis. Kidney Int 90(3):658–664. https://doi.org/10.1016/j.kint.2016.04.003 - DOI - PubMed
    1. Wechalekar AD, Gillmore JD, Hawkins PN (2016) Systemic amyloidosis. Lancet 387(10038):2641–2654. https://doi.org/10.1016/S0140-6736(15)01274-X - DOI
    1. Picken MM (2020) The pathology of amyloidosis in classification: a review. Acta Haematol 11:1–13. https://doi.org/10.1159/000506696 - DOI
    1. Mollee P, Renaut P, Gottlieb D, Goodman H (2014) How to diagnose amyloidosis. Intern Med J 44(1):7–17. https://doi.org/10.1111/imj.12288 - DOI - PubMed
    1. Nienhuis HL, Bijzet J, Hazenberg BP (2016) The prevalence and management of systemic amyloidosis in western countries. Kidney Dis 2(1):10–19. https://doi.org/10.1159/000444206 - DOI

Publication types

LinkOut - more resources